Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

February 1, 2024

https://www.prnewswire.com/news-releases/atara-biotherapeutics-and-pierre-fabre-laboratories-announce-publication-of-phase-3-allele-tab-cel-data-in-the-lancet-oncology-302049771.html

 First Phase 3 Results Published for an Allogeneic T-Cell Therapy

Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients

Read more at prnewswire.com

Related news for (ATRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.